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S2NK Cells—From Bench to Clinic
William J. Murphy,1 Peter Parham,2 Jeffrey S. Miller3After decades of mouse and human research, we now know that natural killer (NK) cells have unique
properties including memory. Although initially described as major histocompatibility complex (MHC)
unrestricted killers, NK cells have several families of receptors that directly recognize MHC including
Ly49 receptors in the mouse and killer immunoglobulin-like receptors (KIR) in humans. The strength of
this signal is determined by polymorphisms in NK cell inhibitory receptor genes and their MHC ligands
inherited on different chromosomes. Inhibitory receptors protect ‘‘self’’-expressing normal tissue from being
killed by NK cells and protecting against autoimmunity. Therefore, for NK cells to kill and produce cytokines,
they must encounter activating receptor ligands in the context of ‘‘missing self’’ that occurs with some viral
infections andmalignant transformation. The second property of inhibitory receptors is to educate or license
NK cells to acquire function. This is best demonstrated in the mouse and in humans by enhanced function on
self-inhibitory receptor-expressing NK cells when in a host expressing cognate ligate. In contrast, NK cells
without inhibitory receptors or with nonself-inhibitory receptors are relatively hyporesponsive. The basic
biology of NK cells in response to cytokines, education, and viruses will translate into strategies to
manipulate NK cells for therapeutic purposes.
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ESTABLISH BIOLOGIC PARADIGMS FOR
HUMAN TRANSLATION
There has been much consternation regarding the
relevance of the mouse for modeling human immune
function and disease states. This is particularly high-
lighted with the study of natural killer (NK) cells. At
a superficial level, there appears to be vast differences
between the two. As with any species as divergent as
mice and humans, there will be significant differences
that always need to be taken into consideration before
extrapolating results. However, there are enough sim-
ilarities that mouse studies ofNK cells have directly in-
formed the clinical use of NK cells. Thus, a more
balanced picture regarding the value of the mouse
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NK cell differentiation, function, and regulation.
NK cells have been an enigma since their activity
was first described in 1964 by Cudkowicz [1] observing
that lethally irradiatedmice could spontaneously reject
bone marrow allografts. Later, these seminal studies
were extended, and the phenomena of hybrid resis-
tance (the ability of F1 hybrid mice to reject parental
bone marrow allografts) was reported by Bennett
et al. [2], which was in direct conflict with the ‘‘laws
of transplantation’’ in which codominant expression
of transplantation antigens (and therefore tolerance)
occurs. The observation of spontaneous major histo-
compatibility complex (MHC)-unrestricted killing of
tumor targets was reported later, and the study of
NK cells as a discrete immune cell type was launched
[3]. Although mouse transplantation studies at times
seemed peculiar and restricted to the mouse rather
than what was observed in clinical settings, it was ex-
actly these studies that paved the way for what we
now know about NK cell biology and led to increasing
interest in their use in clinical transplantation. Indeed,
mouse NK cell studies showed that these cells could
inhibit graft-versus-host disease and promote graft-
versus-tumor effects [4]. These studies led to the sem-
inal report by Ruggeri et al. [5], who showed the value
of bypassing the inhibitory receptors in allogeneic he-
matopoietic cell transplantation (allo-HCT) using
both mouse and human data. This report demon-
strated the usefulness of NK cells to improve outcome
Figure 1. NK cells express a number of inhibitory and activating receptors that determine function. Some of these interactions are definitively estab-
lished with known signaling pathways, while others are less clear. Most receptors interact with cellular targets, but CD16 delivers a potent signal by
binding the Fc portion of immunoglobulin-coated targets. The ability of NK cells to kill a target is determined by the net balance of these inhibitory,
activating, antibody-dependent, and adhesion interactions.
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NK cells are composed of different functional subsets
that contribute to outcome in gastrointestinal stromal
cell tumors [6] suggests that the more we understand
the complex biology of NK cells, the more they can
be of use clinically. It is of interest to note that, despite
the observation that NK cells can detect and reject
allogeneic hematopoietic stem cell grafts was made
over 40 years ago, there is still tremendous uncertainty
regarding the mechanism(s) underlying this process.
NK cell biology has evolved from what was largely
an in vitro activity (MHC-unrestricted killing of tumor
targets) or in vivo bone marrow allograft rejection by
a homogenous population of distinct ‘‘large granular
lymphocytes’’ to a cluster of complex and distinct sub-
populations bearing various inhibitory and activating
receptors in the mouse and in humans (Figure 1).
Mouse studies have led theway regarding the character-
ization of various inhibitory receptors (Ly49, NKG2A,
2B4 although activating in man). Indeed, the postula-
tion of such inhibitory receptors was initially described
by Karre et al. [7] as a means to explain hybrid resis-
tance. The characterization of inhibitory receptors
(Ly49 in mouse and killer cell immunoglobulin-like re-
ceptor [KIR] in humans) has allowed for a mechanism
regarding recognition and control of NK cells. These
inhibitory receptors, which are capable of binding
MHC and MHC-like molecules, are potent because
of ITIM motifs and represent at least a partial mecha-
nism to avoid spontaneous ‘‘self’’ attack [8]. This hasnow evolved with the concept of NK cell ‘‘licensing’’
or ‘‘arming’’ in which NK cells bearing inhibitory re-
ceptors for ‘‘self’’ MHC are allowed to differentiate
and develop into more efficient effector cells [9]. The
mechanism and functions of licensing is not well char-
acterized, and data suggest that NK cells can be
reeducated when transferred into new hosts [10]. There
has been tremendous interest in attempting to ascribe
physiologic NK cell functions with licensing. This has
been controversial, with some reports suggesting that
it is the unlicensed NK phenotype subset that exerts
greater protection under physiologic conditions such
as viral infection [11]. With regard to the physiologic
role of NK cells (other than tumor killing), there has
been ample evidencewith regard to their role in viral in-
fection (cytomegalovirus [CMV] in humans and in
mouse). This data suggests that viruses pirate MHC-
like domains to evade NK cell attack and other viral
proteins bind directly to activating Ly49 receptors in
mice [12]. Distinguishing the role of homologous acti-
vating versus inhibitory receptors in humans is difficult
due to the lack of reagents able to discern them. Inmice,
however, with the exception of 2B4, the activating and
inhibitory receptors can be easily discerned with anti-
bodies. These activating receptors have been exten-
sively studied with evidence of positive selection
occurring during development. Most intriguingly, Sun
et al. [13] has reported evidence forNK ‘‘memory’’ after
expansion of these subsets during viral infection. Thus,
the line between the innate and adaptive arms of the
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gard to NK cells. These receptors also play a critical
role with regard to NK cell expansion. IL-15 has
emerged as the pivotal cytokine required for NK cell
development and maintenance.Whereas mice deficient
in IL-2 (previously, the cytokine of choice to expand
and activate NK cells) have normal NK cells, IL-15-
deficient mice totally lack NK cells [14]. The need for
IL-15 to be ‘‘trans-presented’’ by dendritic cells compli-
cates therapeutic application of this cytokine but also
highlights the need for cellular interactions with NK
cells and other cell types for optimal development and
function. Interestingly, it was recently reported that
commongamma-chain nullmice,which totally lack sig-
naling via this cytokine family (IL-2, IL-7, IL-15) and
are devoid of NK cells, can have NK cells develop via
interaction with viral-activating receptors (Ly49H in
the mouse) and cytokines such as IL-12 [15], indicating
that during pathogeneic states, a much broader picture
of the needs for NK cell development exists.MOUSE VERSUS HUMAN NK
CELLS—SIMILARYET DIFFERENT
Much has been made recently of the differences
between mouse and human NK cells. Clearly, there
are significant differences that can be attributed to spe-
cies divergence and also how inbred mice are gener-
ated and maintained (specific pathogen free, which
may account for the extremely poor lytic ability of rest-
ing mouse NK cells). These differences are high-
lighted by the inhibitory receptors, NK subsets, and
where NK cells reside. Although the NKG2A and D
family members are similar, the KIR (immunoglobulin
superfamily member) and Ly49 (lectin-binding) fami-
lies of molecules are highly divergent with respect to
structure. Importantly, however, their functions are
remarkably similar with regard to binding MHC,
and the mouse studies have paved the way for human
NK receptor delineation and clinical use. Another
key difference with mouse and human NK cells is the
existence of CD56bright and CD56dim subsets in hu-
mans, whereas CD56 is not present onmouseNK. Ad-
ditionally, the demonstration that CD56bright NK cells
reside in the lymph nodes (resting mouse lymph nodes
are relatively devoid of NK cells) and are poorly lytic
suggests other roles for this subpopulation perhaps in
immune regulation. There are othermarkers and func-
tions that distinguish mouse and human NK cells:
CD8 is present on some human NK (mouse NK do
not express), and human NK cells can be expanded
and cultured in vitro for extended periods of time
(mouse NK cells invariably die after several weeks in
culture). It is perhaps revealing given the more exten-
sive similarities between the mouse and humans on the
supposedly more advanced immune system effector
cell: the T cell, whereas the ‘‘simpler’’ NK cell appearsmuch more divergent between the species, suggesting
more recent evolutionary development. Nonetheless,
most of the mouse studies with regard to development
and function have been retrospectively validated in hu-
man studies, and the similarities far outweigh the dif-
ferences. The use of xenogeneic models in which
humanNK orNK progenitors are transferred into im-
munodeficient mice is still far from optimal because of
MHC, adhesion molecule, and cytokine differences
between the species. Large animal models simply do
not have sophisticated reagents to discern subsets,
and it is these subsets where more and more apprecia-
tion ofNK cell biology and function is turning to. This
is especially true when considering the now-
appreciated complex cellular interactions that occur
with NK cells and other immune cell types, the critical
role of MHC in their development as well as organ-
specific interactions (NK cells primarily reside in the
blood, spleen, and liver), which can have a dramatic
impact on clinical extrapolation. Thus, despite the dif-
ferences between mice and humans, especially with re-
gard to NK cells, the similarities have (and continue to
have) resulted in a clearer picture with regard to their
development and function as well as clinical use in can-
cer and other disease states.IMMUNOGENETIC MODULATION OF NK
CELL BIOLOGY
NK cells comprise a heterogeneous subpopulation
of lymphocytes that makes important contributions to
innate immunity, adaptive immunity, and reproduc-
tion. Whereas other subpopulations of lymphocytes,
the B cells and T cells, use rearranging genes to
produce a diversity of antigen receptors, that is not
the case for NK cells. Instead, diverse NK cell pheno-
types are produced by the differential expression of
a wide variety of different cell-surface receptors.
Among these are several classes of receptors that rec-
ognize determinants of MHC class I molecules. In
humans, these comprise certain members of the leuko-
cyte immunoglobulin-like receptor family that recog-
nizes a conserved determinant formed by the a3 and
b2-microglobulin domains of HLA class I, the
CD94:NKG2 receptors that recognize complexes of
conserved HLA-E and peptides derived from the
leader sequences of other HLA class I heavy chains
and members of the KIR family that recognize
polymorphic determinants of HLA-A, -B, and -C.
Whereas the interactions of LILRB1 and
CD94:NKG2 with their ligands are conserved within
the human population, the interactions of KIR with
HLA-A, -B, and -C are highly diversified and provide
the major source of immunogenetic modulation of hu-
man NK cell biology [16]. This modulation occurs
both during the NK cell response and during NK
cell development, when cognate interaction between
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perturbations in HLA class I expression [17-20].
Crystallographic determination of three-dimen-
sional structures has shown that KIR interact with
the upper face of the HLA class I molecule, which
comprises the tops of the a helices of the a1 and a2 do-
mains and the peptide bound between them. This is
the same face with which HLA class I molecules inter-
act with ab T cell receptors (TCR). Although overlap-
ping, the two binding sites are not identical: the TCR
interacts with all the exposed residues of the bound
peptide, but KIR recognition is restricted to peptide
residues 7 and 8. KIR recognition is also restricted to
four epitopes of HLA-A, -B, and -C that are deter-
mined by polymorphisms within residues 79-83 of
the a1 helix. The C1 and C2 epitopes, carried by mu-
tually exclusive subsets of HLA-C allotypes, are deter-
mined by dimorphism at position 80. For the Bw4
epitope carried by subsets of HLA-A and HLA-B allo-
types, arginine 83 is essential, but its function is also
modulated by dimorphism at position 80. The A3/11
epitope appears highly peptide dependant and is less
well characterized than the Bw4, C1, and C2 epitopes.
On the basis of amino acid sequence comparisons,
humanKIR can be divided into four lineages. Of these,
the KIR specific for the C1 and C2 epitopes are of
lineage III, and the KIR specific for the A3/11 and
Bw4 epitopes are of lineage II. KIR2DL4, of
lineage I, recognizes HLA-G and the lineage V KIR,
KIR3DL3, has no known specificity for HLA class I.
The inhibitory KIR specific for C1 (KIR2DL2/3),
C2 (KIR2DL1), and Bw4 (KIR3DL1) are all highly
polymorphic. The amino acid differences that distin-
guish the variants can affect the avidity and/or specific-
ity of the ligand-binding site, the level of cell-surface
expression, the frequency of cellular expression, and
the capacity for signal transduction [21]. Combina-
tions of particular KIR and HLA class I variants are
associated with differential resistance and susceptibil-
ity to a wide range of diseases. These include infectious
and autoimmune diseases, and pregnancy syndromes
[22]. KIR and HLA class I factors can also influence
the success of hematopoietic cell transplantation as
therapy for leukemia.
Because of the strong and variable selection
imposed on NK cells by pressure from defense and
reproduction, MHC class I and KIR are rapidly evolv-
ing, and coevolving, genes. Counterparts to the human
KIR are present only in monkeys and apes, and the
humanKIR system is significantly different from those
observed in other species. Distinguishing the human
KIR locus has been the evolution of two distinctive
groups of haplotypes, the A haplotypes that are
enriched for genes encoding KIR that bind to HLA
class I and the B haplotypes that enriched for genes
encoding KIR that have either reduced or lost their
binding to HLA class I. Both A and B haplotypes arepresent in all populations, although at different relative
frequencies. The results of epidemiologic studies point
to the A haplotypes providing better defense against
infection, whereas the B haplotypes are better for
reproduction [23].EXPLOITING BASIC BIOLOGY TOTREAT
CANCER
Therapeutic strategies using allogeneic NK cells
are based on our understanding of the signaling path-
ways that regulate the antitumor activity of NK cells.
Certain human tumors are more amenable to NK
cell-based immunotherapy, and the degree of sensitiv-
ity to NK-mediated killing is often correlated to their
expression of ligands for activating NK receptors, and
not all tumors are targeted through the interactions
[24]. Most studies have focused on ways to manipulate
the NK effectors to decrease the same interactions be-
tween inhibitory KIR and their MHC ligands. Ini-
tially, algorithms were developed to select NK cell or
stem cell donors to increase the potential for NK cell
alloreactivity. Enthusiasm for this strategy became
widespread after the 2002 report from Perugia, in
which Ruggeri et al. [5] published that KIR ligand
mismatch between patients and their donors was asso-
ciated with improved outcomes in myeloid leukemia
after T cell-deplete haploidentical HCT. We have
made much progress in the understanding of NK cell
function, informed by mouse studies and by detailed
studies of the immunogenetics of NK cell receptors,
and new algorithms have emerged.IMMUNOGENETIC DISCOVERY IMPROVES
TRANSPLANTATION OUTCOME
One such approach to exploit the beneficial effects
ofNK cells after HCT is to consider the KIR genotype
of donor/recipient pairs. Although recipient KIR
genotype had no impact on clinical outcome, in a study
of patients undergoing myeloablative HLA matched
or mismatched unrelated donor HCT for acute mye-
logenous leukemia, the 3-year overall survival rate
was significantly higher after transplantation from
a KIR B/x genotype donor [25]. A subsequent analysis
of 1,409 unrelated donor transplantation recipients re-
fined a beneficial effect of KIR B genes in acute
myelogenous leukemia but not acute lymphoblastic
leukemia, where the most benefit from KIR B geno-
type donors was localized to the centromeric part of
the KIR locus [26]. Donors homozygous for this re-
gion had the most protection from relapse and best
disease-free survival, in both HLA matched and mis-
matched transplants. In this large study, donors could
be stratified byKIR into those with best (Cen-B homo-
zygous present in 11% of the population), better ($2 B
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neutral-donor KIR genotypes. A publically available
calculator to determine this stratification is available
online (www.ebi.ac.uk/ipd/kir/donor_b_content.html),
and a prospective trial using KIR genotyping for donor
selection has begun. For this trial, KIR genotyping as
few as three of the best HLA-matched donor candi-
dates should substantially increase the frequency of
unrelated transplantations from donors with favorable
KIR gene content from 31% to 79%, which is expected
to protect against relapse. The question that remains is
why these gene patterns are protective.UNDERSTANDINGHOWNKCELLS ACQUIRE
FUNCTION
As the first donor-derived lymphocyte subset to
reconstitute following HCT, NK cells may play a piv-
otal role in the graft-versus-leukemia effect, especially
in myeloid leukemia. This has directed attention to
how NK cells acquire function, which remains com-
plex. NK cells can acquire function through several
mechanisms. Although it is well established that NK
cells can be activated by cytokines, there is another
layer of complexity that occurs during NK cell devel-
opment through a process commonly referred to as
licensing or NK cell education [9,27]. Although the
exact timing and location of NK cell education is
unknown, it is generally believed that NK cells
acquire function following engagement of inhibitory
receptors with self-ligand after their differentiation
from hematopoietic progenitors. NK cells lacking
inhibitory receptors for self do exist, but they remain
hyporesponsive and are considered ‘‘uneducated’’
[18]. In the early stages of the NK cell development
in lymph nodes [28], where NK cells are defined in
part by the absence of MHC-specific receptors, these
cells lack both cytotoxicity and cytokine production.
Upon acquisition of CD94/NKG2A, precursor cells
transition to CD56bright NK cells, at which time they
acquire the capacity to produce interferon (IFN)-g.
Still, they display low cytotoxic potential. Only upon
further development and emigration from the lymph
node to the periphery do NK cells acquire CD16 and
KIR and become highly cytotoxic.NKCELLS EARLYAFTERTRANSPLANTATION
ARE PARTIALLY UNEDUCATED
Allo-HCT provides a unique environment in
which to study human NK cell education as it recapit-
ulates NK development from hematopoietic stem cells
in a short interval. It is unknown whether the acquisi-
tion of NK the cytotoxic and cytokine-producing
functions occurs in parallel through interactions with
inhibitory receptors or if distinct signals are requiredto generate each effector function. To understand
the acquisition of NK cell function early after allo-
HCT, use of 9-color flow cytometry to simultaneously
measure both degranulation by CD107a expression (as
a surrogate marker for cytotoxicity) and IFN-g pro-
duction in NK cell subsets has been informative. We
tested a cohort of 30 patients who received either
unmanipulated (T cell replete) or potently T cell-
depleted (CD341 selected) grafts from adult unrelated
donors [29]. Thawed peripheral blood mononuclear
cells were rested overnight in cytokine-free media and
then incubated with K562 cells to trigger cytotoxicity
and cytokine production. Peripheral blood mononu-
clear cells were stained with CD107a (a surrogate for
cytotoxicity), IFN-g, CD56, CD3, CD45, CD158a,
CD158b, CD158e, and CD159a simultaneously.
Cytotoxicity was intact but modestly suppressed
(35%) at 3 months after both T cell-depleted and
T cell-replete HCT with further recovery of killing at
6 months. By contrast, at 3 months after T cell-replete
HCT, there was potent and sustained suppression of
IFN-g production by CD561 cells (57% 6 11% sup-
pression; P 5 .009). The cohort of patients receiving
T cell-depleted (CD34-selected) grafts did not receive
posttransplantation immunosuppression and also ex-
hibited significant suppression of IFN-g at 3 and 6
months after HCT, which was partially restored with
low concentrations of IL-15. We next compared NK
cells that expressed at least one KIR with KIR-negative
NK cells. KIR expression had no effect on cytotoxicity.
In contrast, KIR-positive cells produced significantly
higher amounts of IFN-g than KIR negative cells.
Therefore, followingHCT, expression of KIR discrim-
inates a population of NK cells that produce IFN-g but
does not correlate with cytotoxicity. This suggests that
NKG2A, highly expressed on almost all NK cells early
after transplantation, selectively mediates education
for cytotoxcity but not cytokine production. Because
of their critical antitumor and infection protection roles,
methods toenhancebroad invivoNKcell function, such
as the use of posttransplantation IL-15 administration
are warranted.NK CELLS MATURE ANDACQUIRE
FUNCTION INDUCED BY HUMAN CMV
INFECTION
One example of a unique mechanism that
modulates NK cell function early after transplantation
is that induced by human CMV (hCMV) infection.
This work is based on CMV infection, where a popula-
tion of Ly49H1 NK cells expand and are responsible
for disease clearance through the induction of a ‘‘mem-
oryNK cell response’’ [13].Whether similar events oc-
cur in hCMV infection is unknown. Some studies
suggest that the C-type lectin-like receptor NKG2C
and KIR family may be involved. We studied NK cell
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were triggered by viral reactivation, such that cells were
collected at the time of reactivation and at 2, 4, and 8
weeks later (n 5 10). Most of these patients (nine of
10) received umbilical cord blood transplantation
grafts, which are CMV na€ıve and thus considered
a CMV-negative donor source. NKG2C1NK cells in-
creased following the detection of virus in the blood of
transplantation recipients. The peak response (ie, rise
in NKG2C1 NK cells) was at 4 weeks postinfection.
NK cells that expressed NKG2C produced signifi-
cantly more IFN-g than NK cells that lacked
NKG2C. Four weeks after infection, NK cells that
coexpressed NKG2C and KIR produced significantly
more IFN-g (11.4 6 1.66%) than NK cells that
expressed only KIR but not NKG2C. In the context
of education of KIR1 NK cells through their MHC
ligands, only NKG2C1 NK cells with self-KIR (ie,
NK cells that express KIR where the cognate ligand
is expressed in the recipient) made IFN g: In
contrast, NKG2C1 nonself KIR1NK cells were hypo-
responsive. Remarkably, the expansion and persistence
of mature highly functional NKG2C1KIR1 NK cells
persisted throughout the first year after transplanta-
tion. These findings support the emerging concept of
memory, viral-induced innate cell populations in re-
sponse to hCMV and show that hCMV infection spe-
cifically increases the maturation and functional
competence of NK cells that could be important for
protecting against relapse or subsequent infections.ACKNOWLEDGMENTS
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